Natrol chitosan settlement
This article was originally published in The Tan Sheet
Executive Summary
Supplement manufacturer will pay $250,000 to settle charges regarding lead levels and misleading ad claims for several weight-loss products, firm announces Sept. 13. California district attorneys for the Napa, Solano and Sonoma counties, who brought the charges against the firm, state that Natrol made unsubstantiated fat absorption claims for Chitosan 500 mg and two Ultra Chitosan Fat Intercept products. Lead levels in all three products exceed the 0.5 mcg daily limit allowed by Prop 65, the DAs add. Natrol is barred from making weight-loss claims for any chitosan products without possessing scientific support, and must place Prop 65 warnings on chitosan products that expose the consumer to more than 0.5 mcg of lead daily. Natrol notes it agreed to enter into the stipulated judgment "without defendants admitting to any liability"...
You may also be interested in...
Natrol results
Net sales for the third quarter 2004 increased 20% to $20.9 mil. over the prior-year period, Natrol reports Nov. 15. Net income was $384,000 compared to a loss of $392,000 last year. The Chatsworth, Calif.-based supplement manufacturer incurred $448,000 in legal expenses in the quarter, due in part to a $250,000 settlement of charges related to allegedly unsubstantiated claims and lead levels in several chitosan weight-loss products (1"The Tan Sheet" Sept. 20, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.